RT Journal Article
SR Electronic
T1 Method versatility in RNA extraction-free PCR detection of SARS-CoV-2 in saliva samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268334
DO 10.1101/2021.12.27.21268334
A1 Allicock, Orchid M.
A1 Yolda-Carr, Devyn
A1 Earnest, Rebecca
A1 Breban, Mallery I.
A1 Vega, Noel
A1 Ott, Isabel M.
A1 Kalinich, Chaney
A1 Alpert, Tara
A1 Petrone, Mary E.
A1 Wyllie, Anne L.
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.27.21268334.abstract
AB Early in the pandemic, a simple, open-source, RNA extraction-free RT-qPCR protocol for SARS-CoV-2 detection in saliva was developed and made widely available. This simplified approach (SalivaDirect) requires only sample treatment with proteinase K prior to PCR testing. However, feedback from clinical laboratories highlighted a need for a flexible workflow that can be seamlessly integrated into their current health and safety requirements for the receiving and handling of potentially infectious samples. To address these varying needs, we explored additional pre-PCR workflows. We built upon the original SalivaDirect workflow to include an initial incubation step (95°C for 30 minutes, 95°C for 5 minutes or 65°C for 15 minutes) with or without addition of proteinase K. The limit of detection for the workflows tested did not significantly differ from that of the original SalivaDirect workflow. When tested on de-identified saliva samples from confirmed COVID-19 individuals, these workflows also produced comparable virus detection and assay sensitivities, as determined by RT-qPCR analysis. Exclusion of proteinase K did not negatively affect the sensitivity of the assay. The addition of multiple heat pretreatment options to the SalivaDirect protocol increases the accessibility of this cost-effective SARS-CoV-2 test as it gives diagnostic laboratories the flexibility to implement the workflow which best suits their safety protocols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Tempus Labs, Inc (A.L.W), Yale Center for Clinical Investigation TL1 TR001864 (M.E.P.) and Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (A.L.W).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Yale Human Research Protection Program gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.